RYTM Stock Summary and Trading Ideas (Rhythm Pharmaceuticals | NASDAQ:RYTM)

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Rhythm Pharmaceuticals trades on the NASDAQ stock market under the symbol RYTM.

As of March 11, 2026, RYTM stock price declined to $90.02 with 565,496 million shares trading.

RYTM has a beta of 1.34, meaning it tends to be more sensitive to market movements. RYTM has a correlation of 0.19 to the broad based SPY ETF.

RYTM has a market cap of $6.01 billion. This is considered a Mid Cap stock.

Last quarter Rhythm Pharmaceuticals reported $57 million in Revenue and -$.73 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.05.

In the last 3 years, RYTM traded as high as $122.20 and as low as $15.50.

The top ETF exchange traded funds that RYTM belongs to (by Net Assets): VTI, VB, IWM, XBI, VBK.

RYTM has outperformed the market in the last year with a return of +85.4%, while the SPY ETF gained +21.9%. However, in the most recent history, RYTM shares have underperformed the stock market with its stock returning -14.1% in the last 3 month period and -8.7% for the last 2 week period, while SPY has returned -1.3% and -1.6%, respectively.

RYTM support price is $89.84 and resistance is $96.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RYTM shares will trade within this expected range on the day.